The issues of medicinal provision for patients after transplantation were discussed today during a round table chaired by the Minister of Health of the Republic of Kazakhstan Elzhan Birtanov.

The round table was also attended by the Chairman of the Pharmacy Committee Lyudmila Byurabekova, acting. Chairman of the Board of SK- Pharmaceuticals LLP Asemgul Erzhanova, First Deputy Director General of the National Center for Drug Expertise Arnur Nurtayev, Head of the Center for the rational use of medicines Gulzira Zhusupova, representatives of public organizations representing the interests of patients after transplantation, as well as experts in the field of transplantation, pharmacology, employees of the Ministry of Health and the Single Distributor.

The decision to hold the round table was made after the appeal of public organizations of patients after transplantation regarding the purchase of the generic drug Mycophenolate Mofetil capsules 250 mg, manufactured by Hetero Labs Limited, India, following the tender of the Single Distributor.

During the round table, the president of the NGO "Society of patients before and after transplantation" Өmіr Siyyı "expressed their doubts about the possibility of a painless transition from the drug they used to the purchased by the results of the tender" Sandugash Orynbayeva, chairman of the NGO for the rehabilitation of transplanted patients "Өмір t" Zhanibek Uspanov and the head Public organization "Society of patients with a transplanted kidney" Senim "Erzhan Mukhamadiev.

Arnur Nurtayev, first deputy director general of the National Center for Drug Expertise, spoke about the confirmation of the effectiveness of the purchased product. According to him, according to clinical trials, the bioequivalence of the drug Mycophenolate mofetil is comparable to the reference drug. "Clinical differences in the portability and safety between the original and the generic were not observed. The indicators confirm that this generic is bioequivalent to the original. "

He also said that there is sufficient evidence to support the possibility of generic replacement of mycophenolic acid. "The data of a number of studies of mycophenolic acid indicate that the transition is possible without loss of effect," Arnur Nurtayev said.

During the discussion, the positions of doctors and pharmacologists regarding the use of the purchased generic were also heard.

Rounding out the roundtable, Yelzhan Birtanov emphasized the readiness of the Ministry of Health and the Single Distributor to discuss emerging issues. "We always prioritize patients. At the same time, the use of generics is a comprehensive solution for providing affordable and high-quality medicines to a wide range of people both in the world and in Kazakhstan, "the Minister noted.

Based on the results of the discussion, Minister of Health Elzhan Birtanov instructed the Committee of Pharmacy, SK- Pharmaceuticals and the expert community to conduct an in-depth analysis of the issue, identify the existing risks and work out a joint solution to the problem in full compliance with the current legislation and to prepare another discussion by the same composition of participants in the near future.